DaVita Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: November-2026Ownership Structure
Ownership Analysis
Berkshire's roughly 45% stake gives DaVita a much more concentrated ownership structure than a typical large healthcare provider. Its approximately 28.88 million shares in June 2026 filings dwarf the next institutions' positions. Nevertheless, the company remains public, with a separate board and contractual arrangements governing Berkshire's investment.We regard the standstill and share-repurchase agreement as central to understanding control. When the relevant threshold is reached, quarterly repurchases from Berkshire are designed to return its ownership to 45%, preventing ordinary company buybacks from mechanically producing an unchecked increase. This arrangement does not remove the influence of such a large investor. It changes how that influence is maintained. The board must still balance repurchases with debt obligations, technology investment and clinical operations supporting $13.643 billion of 2025 revenue.A stake near 45% is also different from a dispersed group of several institutions that happen to own a similar total percentage. Berkshire provides one concentrated economic interest with substantial potential influence, while the remaining shares are distributed among investors with different mandates. That can support a longer investment horizon, but it makes the protection of minority interests especially important. Alignment with the largest shareholder is insufficient evidence that a repurchase or other capital commitment benefits every owner equally.The operating company's cash obligations remain the foundation of that assessment. Dialysis requires dependable staffing, supplies, facilities and information systems, so the board cannot treat all cash generation as available for financial engineering. The repurchase mechanism regulates the evolution of Berkshire's stake; it does not eliminate the effect of buybacks on leverage or liquidity. A sound ownership structure should allow appropriate capital returns while preserving resources for the treatment network. The practical test is whether the financing policy remains compatible with resilient clinical operations, including periods when reimbursement, patient mix or operating costs move against the business.
Direct Owners
Institutional Shareholders
Shareholder Analysis
DaVita's 2026 proxy listed Berkshire at 45.5% in March, while subsequent June filings showed approximately 28.88 million Berkshire shares and a stake near 45%. The reduction in shares is consistent with a structure in which Berkshire sells into company repurchases as the overall share count contracts. It should not automatically be interpreted as abandonment of the investment.BlackRock's approximately 3.85% and Vanguard Capital Management's 3.27% are much smaller in the June positions. That imbalance shapes the governance and liquidity available to other minority investors. DaVita repurchased approximately $1.788 billion of stock in 2025, materially reducing the share count. Per-share growth can therefore outpace operating growth. Owners need to distinguish that arithmetic benefit from genuine improvement in treatment economics, cash generation and financial resilience.The distinction between share sales and a change in economic commitment is unusually important for this register. Under the agreement, a reduction in Berkshire's absolute holdings can accompany a broadly maintained percentage interest. Looking only at the number of shares sold would therefore risk misreading a contractual adjustment as a new negative investment judgment. We also distinguish that mechanism from a promise to support DaVita financially under all circumstances. A large shareholder's willingness to retain equity does not replace the company's own responsibility to generate cash and manage its financing commitments.Other holders participate in the same common-equity economics but with much less individual voting influence. Their investment outcome depends on both operating performance and the terms on which the company retires shares. If cash is used effectively, a lower share count can increase each remaining owner's claim on future earnings. If repurchases weaken resilience or occur at unattractive prices, concentration can rise without creating equivalent value. The institutional register consequently needs to be considered alongside the funding of the program, the condition of the balance sheet and the treatment economics supporting the continuing business.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| DaVita Kidney Care | Brand | United States outpatient hospital and home dialysis services |
| DaVita Integrated Kidney Care | Brand | Kidney disease management and risk-based care arrangements |
| DaVita International | Brand | Dialysis operations outside the United States |
| DaVita Clinical Research | Subsidiary | Clinical research services for kidney disease and other studies |
| DaVita Labs | Brand | Clinical laboratory services supporting dialysis treatment |
| DaVita Venture Group | Brand | Investment and partnership platform for kidney care innovation |
| DaVita UK | Subsidiary | United Kingdom dialysis operations |
| DaVita Tratamento Renal | Subsidiary | Brazilian dialysis services business |
Portfolio Analysis
DaVita's portfolio is organized around the kidney patient's care journey rather than a broad collection of unrelated medical brands. Kidney Care delivers dialysis across outpatient, hospital and home settings, while Integrated Kidney Care coordinates patients under risk-based arrangements. Clinical Research and laboratory services support the same clinical infrastructure.International operations extend the model into different reimbursement and regulatory systems. At year-end 2025, they supported 585 outpatient centers in 14 countries outside the United States. International services offer another source of growth, but the company's approximately 36% United States dialysis patient share remains central to its economics. HealthCare Partners belongs in the acquisition history rather than the current portfolio, because the physician group was sold to Optum in 2019. The present $13.643 billion revenue base reflects the continuing kidney care group.The supporting services can deepen the value of the clinical network when they improve how patients move between settings or how clinicians manage treatment. Laboratory information and integrated care capabilities are particularly relevant to a business that serves people with ongoing, complex medical needs. Their contribution to care delivery and unit economics matters more than an independent franchise valuation attached to each separate name. The common operating focus is useful, but it also leaves much of the group exposed to the same reimbursement and patient-population risks.International growth broadens geography without necessarily creating the same operating economics as the United States business. Payment systems, local demand and staffing conditions differ, so a new clinic abroad cannot automatically be valued as equivalent to a mature domestic location. The Latin American acquisitions add to a platform that already serves a substantial patient base outside the United States. Their portfolio value depends on combining scale with local execution. The resulting group is more geographically extensive, while remaining centered on kidney care rather than reversing the earlier decision to exit the broader physician-services business.
Market Share & Competitors
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| DaVita ★ | 36% | $13.643B | FY2025 United States dialysis patient share and global group revenue |
| Fresenius Medical Care | 37% | N/A | FY2025 United States dialysis patient share and vertically integrated supplies |
| US Renal Care | N/A | N/A | United States dialysis services and physician partnerships |
| Dialysis Clinic Inc. | N/A | N/A | Nonprofit United States dialysis services |
| Satellite Healthcare | N/A | N/A | Nonprofit dialysis and home treatment services |
Competitive Analysis
DaVita estimates that it serves approximately 36% of United States dialysis patients, while Fresenius Medical Care reports roughly 37% in that market. These patient shares describe a concentrated services industry, not the global market for dialysis machines or pharmaceutical treatments. Fresenius also manufactures equipment and supplies, giving it a different degree of vertical integration.We consider payer mix and treatment economics more informative than clinic count alone. Government programs supplied approximately 68% of DaVita's United States dialysis patient service revenue for about 89% of patients in 2025. Commercial reimbursement therefore has disproportionate financial importance. The $3.578 billion of third-quarter 2026 group revenue must support staffing, supplies and technology while reimbursement changes and new kidney therapies alter demand. Home treatment and integrated care offer opportunities but also require continued execution.The patient shares also need to be read alongside the distinctive requirements of dialysis. Treatments are recurring and clinically necessary, but providers still compete on access, quality, physician relationships and the convenience of available settings. A large network can spread certain operating capabilities across many locations, while local execution remains decisive for the patient experience. Market concentration alone cannot guarantee attractive returns. A provider can serve a substantial number of patients and still face pressure if reimbursement changes or the cost of staffing and supplies rises faster than revenue per treatment.Fresenius's equipment and supplies business creates another difference from DaVita's service-centered profile. Vertical integration can affect the competitive relationship, but it also gives Fresenius exposure to product markets that should not be mixed with United States dialysis patient shares. For DaVita, home treatment and integrated care can improve the service offering while requiring technology, training and coordination. The financial opportunity is to deliver appropriate care more effectively, rather than simply move activity between settings. Durable advantage would be visible in dependable clinical operations and favorable economics after the full cost of serving patients across the network.
Acquisitions
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Renal Treatment Centers | undisclosed | 1998 | Historical dialysis network combination under Total Renal Care |
| Gambro Healthcare US | $3.05B | 2005 | United States dialysis clinic acquisition with antitrust divestitures |
| HealthCare Partners | $4.42B | 2012 | Physician group acquired for cash and stock and later sold as DaVita Medical Group |
| Renal Ventures | undisclosed | 2017 | Dialysis clinic acquisition subject to divestitures |
| Fresenius Latin American dialysis operations | $300M | 2024 | Four country transactions covering Brazil Colombia Chile and Ecuador with closings completed in stages through 2025 |
Acquisitions Analysis
The $3.05 billion Gambro Healthcare US purchase in 2005 expanded dialysis scale and established a much broader treatment network. HealthCare Partners, acquired for approximately $4.42 billion in 2012, was a more ambitious move into coordinated physician services. That business was later sold to Optum, making it a completed acquisition and subsequent exit rather than a current subsidiary.More recent international investment is closer to DaVita's core operating model. The $300 million set of transactions with Fresenius covered dialysis operations in Brazil, Colombia, Chile and Ecuador, with closings occurring in stages. The larger network can apply established clinical and operating capabilities across more patients. Local reimbursement, integration costs and staffing remain decisive. Acquiring treatment volume produces value only when the resulting cash flow exceeds the purchase and ongoing investment costs.The historical physician transaction also provides a useful caution about assuming that adjacency guarantees integration value. HealthCare Partners addressed the wider care needs of a patient population, while dialysis remained a specialized recurring service. The combination broadened the company's activities, but the later sale changed the direction of capital allocation. The capital committed, cash subsequently recovered and capabilities retained provide a better assessment of that sequence than a comparison of headline prices that ignores changes in the businesses and the timing of their cash flows.The staged Latin American purchases have a more direct connection to the retained clinical model, yet closing across several jurisdictions introduces its own operating requirements. The strategic benefit comes from acquiring services that DaVita can support competently, not merely from expanding the map of countries served. Integration must preserve patient continuity, staff capability and acceptable local reimbursement economics. Earlier large acquisitions established network scale; newer investments need to demonstrate that scale can be converted into sustainable cash returns. Their success should ultimately appear in the quality of the continuing kidney care franchise rather than an increasing transaction count.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
DaVita's 2012 combination with HealthCare Partners created a broader healthcare services group and changed the parent name to DaVita HealthCare Partners. The eventual sale of DaVita Medical Group to Optum for $4.34 billion in 2019 reversed that expansion. The continuing public company retained its dialysis and kidney care operations.The sale changed business scope while leaving DaVita independent of UnitedHealth. The distinction is particularly important because the acquired physician assets continued within Optum while the DVA ticker remained independent. Earlier Gambro and Renal Treatment Centers combinations built scale in the retained core. International acquisitions now extend that core geographically. The resulting $13.643 billion 2025 revenue base consequently has a different risk profile from the temporarily broader physician-and-dialysis group.The physician sale also changed the meaning of the DaVita name for investors who had followed the combined group. The parent retained the ticker and a major treatment network, while the divested assets moved into a different corporate system. It is therefore inaccurate to treat the transaction as a transfer of the entire listed company's ownership to Optum. We see the distinction as essential to understanding both the contemporary shareholder register and the services that belong in the current portfolio. Transaction descriptions should follow the specific assets transferred, rather than the familiarity of the names involved.The earlier combinations show a different form of restructuring, in which acquisitions consolidated dialysis operations and expanded the core service platform. The company has consequently used mergers to gain scale and a disposal to reduce scope. Those are compatible choices when applied to different operating problems. The quality of the outcome depends on what remains after each event: clinical capabilities, cash-generating assets, financial obligations and the need for further investment. The renewed geographic expansion around kidney care fits that retained identity, while the former physician operation should remain part of the historical record rather than the continuing ownership chain.
Ownership History
Ownership History Analysis
DaVita's ownership history combines a public-company turnaround with the gradual emergence of a dominant outside shareholder. The operating lineage began in 1979, and the independent Total Renal Care business completed its initial public offering in 1994. Severe difficulties in the late 1990s preceded the DaVita name and a renewed operating focus in 2000.Berkshire began accumulating shares in 2011 and became increasingly prominent as DaVita repurchased stock. The 2024 repurchase agreement introduced a mechanism targeting 45% Berkshire ownership after specified quarterly settlements. That arrangement defines the recent evolution of shareholder structure. The company retired approximately 12.7 million shares for $1.788 billion in 2025, illustrating how capital allocation can concentrate ownership without a conventional takeover or a large new block purchase by the leading investor.The turnaround period also makes continuity of a stock listing an incomplete description of the shareholder experience. The business had to restore its operating and financial footing before later acquisitions could build the present scale. The DaVita identity became associated with that renewed focus, but the economic claim remained a public investment rather than a new privately controlled enterprise. Management's turnaround role should be distinguished from ownership control. An influential executive can shape operations without holding the kind of common-equity position Berkshire subsequently accumulated through its investment activity.The later growth of Berkshire's percentage illustrates how capital allocation can reshape a register even when the company remains independently listed. Repurchases retire outside claims, and a continuing large holder becomes proportionally more important unless it also reduces its shares. The contractual mechanism formalized how that relationship would be managed. For investors evaluating the history, the meaningful conclusion is not simply that Berkshire is large. It is that public governance, concentrated influence and a sustained repurchase policy now operate together, with the clinical business responsible for producing the cash that supports the financial arrangements.
Ownership Explained
DaVita is a publicly traded kidney care company owned by shareholders of NYSE-listed DVA stock. Berkshire Hathaway is by far its largest shareholder, with approximately 28.88 million shares in June 2026 institutional filings, or roughly 45% of the common stock. DaVita remains separately listed and is not a wholly owned Berkshire subsidiary. BlackRock, Vanguard managers, Morgan Stanley and State Street hold smaller minority positions.The company's roots reach back to Medical Ambulatory Care in 1979. The modern independent public business developed as Total Renal Care and adopted the DaVita name in 2000 after a difficult financial turnaround. Its 2005 Gambro acquisition expanded dialysis scale, while the 2012 HealthCare Partners transaction moved into broader physician services. DaVita sold that physician group, then known as DaVita Medical Group, to Optum in 2019. Optum does not own DaVita's continuing dialysis group.DaVita reported $13.643 billion of 2025 revenue and approximately 78,000 employees. Third-quarter 2026 revenue was $3.578 billion. Its portfolio centers on dialysis, home treatment, integrated kidney care, laboratory support and international services. A share-repurchase agreement requires quarterly purchases from Berkshire when its stake reaches the contractual threshold, with the objective of returning that holding to 45%. Consequently, Berkshire can sell shares while remaining the dominant minority investor.The business earns most of its revenue from recurring kidney care rather than from ownership of a broad health insurance portfolio. Its clinical network combines treatment settings and supporting services, while international expansion introduces additional local reimbursement and regulatory systems. The concentrated shareholder base sits above those operating relationships. Berkshire's financial involvement does not replace the responsibilities of DaVita's directors, management or clinicians. For ordinary investors, the important connection is between treatment economics, the cash required to maintain service quality and the amount available for debt obligations or repurchases. Those factors determine what the large ownership percentage means economically over time.
DaVita's large Berkshire holding makes shareholder concentration a practical governance issue, even without majority ownership. The standstill and repurchase arrangements shape how that position develops as DaVita retires shares from other investors.Patients and clinicians depend primarily on continuity of treatment, staffing, clinical quality and reimbursement relationships. Berkshire's investment does not make it the direct operator of dialysis centers. For other shareholders, repurchases can increase their proportional interest, but also consume cash and affect leverage. The continuing business must be distinguished from the physician group sold to Optum, because ownership of DaVita Medical Group does not extend to the separately listed DaVita parent.